DataMEDS SI Provides Business Update On CLIA Lab Helomics And Its Super Intelligence Predictive Oncology Division
Key Highlights
- ➤DataMeds cut corporate management positions to fund ChemoFx commercialization
- ➤ChemoFx added to Humana Medicaid coverage policy for gynecologic cancers
- ➤ChemoFx historical peak annual revenue exceeded $25 million
- ➤Predictive Oncology repository contains over 70,000 samples across 130 tumor types
- ➤DataMeds plans hospital and payer collaborations to expand ChemoFx testing
Expert Statements
Gerald E. Commissiong, Interim Co-CEO of DataMEDS
“The ChemoFx test has been commercially available in the United States since 1997, has two dedicated CPT codes (81535/81536) and has been optimized through continual automation improvements for high test volumes, with peak historical annual revenues previously exceeding $25 million under prior ownership”
Gerald E. Commissiong, Interim Co-CEO of DataMEDS
“Leveraging DataMEDS' management team's deep relationships in oncology, we are preparing to relaunch a marketing campaign for ChemoFx. A landmark 2015 peer-reviewed publication in PLOS reviewed evidence supporting the clinical utility and cost-effectiveness of using the ChemoFx Assay for chemotherapy regimen selection in epithelial ovarian cancer (EOC). Based on our review of data generated since that publication, we believe there is an opportunity to publish additional clinical utility data for the ChemoFx Assay in other solid tumors, and we are preparing these additional data analyses for peer-review.”
Gerald E. Commissiong, Interim Co-CEO of DataMEDS
“Predictive Oncology controls a repository of over 70,000 de-identified tumor samples linked to de-identified clinical data in over 130 tumor types, including approximately 20,000 ovarian cancer samples. The Company intends to seek research collaborations, including with super intelligence (artificial intelligence) frontier lab developers, using de-identified data generated from its tumor samples. These potential collaborations could enable the discovery of new therapeutic targets leveraging the sample repository and the Company's proprietary organoid technology. The Company has begun discussions with hospital systems, Health Maintenance Organizations (HMOs), Group Purchasing Organizations (GPOs) and specialty cancer treatment centers to add ChemoFx to their cancer testing programs where appropriate.”
TAMPA, FL / ACCESS Newswire / October 13, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its super intelligence platform EinsteinRx(™) and smart contracts platform PharmacyChain(™), today announced that it has implemented cost control measures, primarily through reductions in corporate management positions, to focus the workforce spend on commercializing ChemoFx(®) as a diagnostic lab test to help oncologists inform their chemotherapy regimen selection, initially for gynecologic cancers only. ChemoFx has recently been included, for the first time, in a Humana Medicaid coverage policy for gynecologic cancers.
Today's announcement comes following the September 11, 2026, DataMEDS acquisition of Helomics Corporation, which included Helomics' Predictive Oncology Cancer Biomarker Super Intelligence (SI) division.
Get started
Create a free account to read the full story.